GlassScriptPhysician profile
Hong Xiao
NPI 1669434601
$9,900.31
in general payments reported to CMS, 2019-2025
35 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 88% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $1,525 · 2021: $1,791 · 2022: $1,233 · 2023: $1,034 · 2024: $1,252 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,597.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,683.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,603.86 | 2019-2025 | Arexvy, Trelegy Ellipta, Penmenvy |
| Novo Nordisk INC | $1,431.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,055.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $651.05 | 2019-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $607.78 | 2019-2024 | |
| Amarin Pharma, INC. | $561.20 | 2019-2022 | |
| Gilead Sciences, INC. | $505.63 | 2019-2022 | |
| Amgen INC. | $250.19 | 2022-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $209.83 | 2019-2025 | Gardasil 9, Capvaxive, Vaqta |
| Phathom Pharmaceuticals, INC. | $163.12 | 2023-2025 | Voquezna |
| Dexcom, INC. | $149.28 | 2019-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $130.42 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.77 | 2022-2023 | |
| Abbott Laboratories | $124.06 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $101.03 | 2023-2025 | Cologuard Collection Kit |
| Zimmer Biomet Holdings, INC. | $73.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.10 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.39 | 2020-2024 | Trulance, Xifaxan |
| Sanofi Pasteur INC. | $43.43 | 2019-2023 | |
| Abbvie INC. | $35.55 | 2021 | |
| Phadia US INC. | $35.32 | 2019-2023 | Immunocap |
| Seqirus USA INC | $35.28 | 2021-2024 | Flucelvax, Fluad |
| Redhill Biopharma INC. | $25.70 | 2020 | |
| Idorsia Pharmaceuticals US INC | $23.44 | 2025 | Quviviq |
| Dynavax Technologies Corporation | $20.87 | 2023 | Heplisav-B |
| Ibsa Pharma INC. | $20.31 | 2025 | Licart, Flector, Tirosint |
| Si-Bone, INC. | $20.26 | 2022 | |
| Biotronik Nro, INC. | $19.49 | 2024 | Prospera |
| Alkermes, INC. | $18.19 | 2023 | Vivitrol |
| Genentech USA, INC. | $17.05 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.76 | 2020 | |
| Lucid Diagnostics INC. | $13.40 | 2023 | |
| Eisai INC. | $12.39 | 2020 | |
| Aytu Biopharma, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Xiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.